C4 Therapeutics

Founded 2015 · CIK 0001662579 · Biotech · Public

Protein degraders (small molecules that induce targeted protein degradation) for cancer treatment

c4therapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$70M
1 Form D · Jan 2016
129 months since last filing
Contracts
—
No federal contracts on record
Patents
40
22 granted · 18 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$70,315,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1982CytomX Therapeutics—$143M
1983POP ART, INC.—$1.0M
1984NEURAEGIS INC——
1985C4 Therapeutics—$70M
1986LIKARDA LLC——
1987NATURA THERAPEUTICS, INC.——
1988Ultimaxx Health, LLC—$10M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Kenneth AndersonDirector
  • Bihua ChenDirector
  • Alain CohenDirector
  • Marc CohenDirector · Executive Officer
  • Bruce DowneyDirector
  • Jay EastmanDirector
  • Jason FishermanDirector · Executive Officer
  • Ronald KaiserDirector
  • Elena ProkupetsDirector
  • Malcolm SalterDirector
  • William ScalzulliDirector
  • Miles StuchinDirector

Patents

USPTO · 22 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.